论文部分内容阅读
目的:研究匹多莫德治疗反复呼吸道感染患儿的临床疗效,并探讨其对患儿外周血T淋巴细胞亚群变化的影响。方法:选择我院收治的160例反复呼吸道感染患儿,根据临床治疗方法将其分成研究组(80例)与对照组(80例),对照组采用抗生素或抗病毒、退热、止咳、平喘与化痰等对症治疗,研究组则在对照组的基础上再加用匹多莫德口服。比较两组患儿外周血T淋巴细胞亚群变化并分析其临床疗效。结果:研究组治疗总有效率显著优于对照组(P<0.05)。研究组治疗后CD3+、CD4+、CD4+/CD8+水平,与治疗前比较明显升高(P<0.05),与对照组同期比较具有明显的差异(P<0.05)。研究组患儿治疗后白细胞计数及中性粒细胞水平,与治疗前比较无明显差异(P>0.05),与对照组同期比较无明显差异(P>0.05);对照组治疗前后白细胞计数及中性粒细胞水平无明显差异(P>0.05)。研究组患儿咳嗽、发热、喘息、肺部啰音消失时间以及抗生素使用时间均明显少于对照组(P<0.01)。研究组与对照组患儿治疗过程中均未发生明显的药物不良反应。结论:匹多莫德治疗反复呼吸道感染患儿疗效确切,能有效改善T淋巴细胞的免疫功能,值得临床推广与应用。
Objective: To study the clinical efficacy of pidotimod in children with recurrent respiratory tract infections and to explore its effect on the changes of T lymphocyte subsets in children. Methods: A hospital, 160 patients with recurrent respiratory infections in children, according to the clinical study will be divided into treatment group (80 cases) and control group (80 cases) and control group antibiotic or antiviral, fever, cough, flat Asthma and phlegm and other symptomatic treatment, the study group is based on the control group plus Pidotomide oral. The changes of T lymphocyte subsets in peripheral blood of two groups were compared and their clinical effects were analyzed. Results: The total effective rate of the study group was significantly better than that of the control group (P <0.05). The levels of CD3 +, CD4 + and CD4 + / CD8 + in the study group after treatment were significantly higher than those before treatment (P <0.05), which were significantly different from those in the control group at the same period (P <0.05). The white blood cell count and the level of neutrophil in the study group after treatment were not significantly different from those before the treatment (P> 0.05), but there was no significant difference between the control group and the control group (P> 0.05) No significant difference in the level of neutrophil (P> 0.05). The study group cough, fever, wheezing, pulmonary rales disappear time and duration of antibiotics were significantly less than the control group (P <0.01). No significant adverse drug reactions occurred in the treatment group and control group. Conclusion: Pidotimod treatment of recurrent respiratory tract infection in children with exact effect, can effectively improve the immune function of T lymphocytes, worthy of clinical promotion and application.